vs

Side-by-side financial comparison of LEGALZOOM.COM, INC. (LZ) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $190.3M, roughly 1.7× LEGALZOOM.COM, INC.). LEGALZOOM.COM, INC. runs the higher net margin — 3.2% vs -18.2%, a 21.4% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 17.7%). LEGALZOOM.COM, INC. produced more free cash flow last quarter ($28.0M vs $-133.8M).

LegalZoom.com, Inc. is an American online legal technology and services company launched in 2001. It provides online legal services using an independent network of attorneys and the LegalZoom-owned law firm, LegalZoom Legal Services, as well as self-service technology and care specialists. Services include wills and living trusts, business compliance such as licenses and permits, copyright registrations, and trademark applications. The company also offers attorney referrals and registered age...

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

LZ vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.7× larger
MDGL
$321.1M
$190.3M
LZ
Growing faster (revenue YoY)
MDGL
MDGL
+193.1% gap
MDGL
210.8%
17.7%
LZ
Higher net margin
LZ
LZ
21.4% more per $
LZ
3.2%
-18.2%
MDGL
More free cash flow
LZ
LZ
$161.8M more FCF
LZ
$28.0M
$-133.8M
MDGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LZ
LZ
MDGL
MDGL
Revenue
$190.3M
$321.1M
Net Profit
$6.1M
$-58.6M
Gross Margin
67.6%
Operating Margin
6.6%
-18.6%
Net Margin
3.2%
-18.2%
Revenue YoY
17.7%
210.8%
Net Profit YoY
-52.9%
1.4%
EPS (diluted)
$0.03
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LZ
LZ
MDGL
MDGL
Q4 25
$190.3M
$321.1M
Q3 25
$190.2M
$287.3M
Q2 25
$192.5M
$212.8M
Q1 25
$183.1M
$137.3M
Q4 24
$161.7M
$103.3M
Q3 24
$168.6M
$62.2M
Q2 24
$177.4M
Q1 24
$174.2M
$0
Net Profit
LZ
LZ
MDGL
MDGL
Q4 25
$6.1M
$-58.6M
Q3 25
$4.5M
$-114.2M
Q2 25
$-266.0K
$-42.3M
Q1 25
$5.1M
$-73.2M
Q4 24
$12.9M
$-59.4M
Q3 24
$11.1M
$-107.0M
Q2 24
$1.3M
Q1 24
$4.7M
$-147.5M
Gross Margin
LZ
LZ
MDGL
MDGL
Q4 25
67.6%
Q3 25
67.3%
Q2 25
65.0%
Q1 25
63.7%
96.7%
Q4 24
67.0%
Q3 24
67.5%
Q2 24
64.1%
Q1 24
60.7%
Operating Margin
LZ
LZ
MDGL
MDGL
Q4 25
6.6%
-18.6%
Q3 25
3.4%
-39.7%
Q2 25
-1.6%
-22.2%
Q1 25
4.9%
-57.8%
Q4 24
8.1%
-64.8%
Q3 24
9.6%
-187.1%
Q2 24
0.6%
Q1 24
2.9%
Net Margin
LZ
LZ
MDGL
MDGL
Q4 25
3.2%
-18.2%
Q3 25
2.4%
-39.8%
Q2 25
-0.1%
-19.9%
Q1 25
2.8%
-53.4%
Q4 24
7.9%
-57.5%
Q3 24
6.6%
-172.0%
Q2 24
0.7%
Q1 24
2.7%
EPS (diluted)
LZ
LZ
MDGL
MDGL
Q4 25
$0.03
$-2.55
Q3 25
$0.02
$-5.08
Q2 25
$0.00
$-1.90
Q1 25
$0.03
$-3.32
Q4 24
$0.07
$-2.50
Q3 24
$0.06
$-4.92
Q2 24
$0.01
Q1 24
$0.02
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LZ
LZ
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$203.1M
$198.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$171.9M
$602.7M
Total Assets
$511.5M
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LZ
LZ
MDGL
MDGL
Q4 25
$203.1M
$198.7M
Q3 25
$237.2M
$295.7M
Q2 25
$217.0M
$186.2M
Q1 25
$210.0M
$183.6M
Q4 24
$142.1M
$100.0M
Q3 24
$112.5M
$232.7M
Q2 24
$118.8M
Q1 24
$228.1M
$622.5M
Total Debt
LZ
LZ
MDGL
MDGL
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Q1 24
$116.1M
Stockholders' Equity
LZ
LZ
MDGL
MDGL
Q4 25
$171.9M
$602.7M
Q3 25
$201.9M
$625.7M
Q2 25
$194.1M
$696.0M
Q1 25
$187.2M
$710.6M
Q4 24
$93.3M
$754.4M
Q3 24
$60.1M
$777.2M
Q2 24
$60.8M
Q1 24
$167.9M
$850.8M
Total Assets
LZ
LZ
MDGL
MDGL
Q4 25
$511.5M
$1.3B
Q3 25
$551.1M
$1.4B
Q2 25
$543.0M
$1.0B
Q1 25
$532.7M
$996.6M
Q4 24
$373.9M
$1.0B
Q3 24
$348.8M
$1.1B
Q2 24
$359.5M
Q1 24
$459.7M
$1.1B
Debt / Equity
LZ
LZ
MDGL
MDGL
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LZ
LZ
MDGL
MDGL
Operating Cash FlowLast quarter
$34.1M
$-133.5M
Free Cash FlowOCF − Capex
$28.0M
$-133.8M
FCF MarginFCF / Revenue
14.7%
-41.7%
Capex IntensityCapex / Revenue
3.2%
0.1%
Cash ConversionOCF / Net Profit
5.63×
TTM Free Cash FlowTrailing 4 quarters
$147.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LZ
LZ
MDGL
MDGL
Q4 25
$34.1M
$-133.5M
Q3 25
$54.2M
$79.8M
Q2 25
$39.1M
$-47.1M
Q1 25
$50.7M
$-88.9M
Q4 24
$42.6M
$-104.5M
Q3 24
$31.6M
$-67.0M
Q2 24
$27.2M
Q1 24
$34.2M
$-149.2M
Free Cash Flow
LZ
LZ
MDGL
MDGL
Q4 25
$28.0M
$-133.8M
Q3 25
$47.0M
$79.0M
Q2 25
$31.6M
Q1 25
$41.3M
Q4 24
$35.9M
$-104.7M
Q3 24
$22.0M
$-67.8M
Q2 24
$17.4M
Q1 24
$24.7M
$-149.5M
FCF Margin
LZ
LZ
MDGL
MDGL
Q4 25
14.7%
-41.7%
Q3 25
24.7%
27.5%
Q2 25
16.4%
Q1 25
22.6%
Q4 24
22.2%
-101.3%
Q3 24
13.0%
-109.0%
Q2 24
9.8%
Q1 24
14.2%
Capex Intensity
LZ
LZ
MDGL
MDGL
Q4 25
3.2%
0.1%
Q3 25
3.8%
0.3%
Q2 25
3.9%
0.0%
Q1 25
5.1%
0.0%
Q4 24
4.1%
0.2%
Q3 24
5.7%
1.3%
Q2 24
5.6%
Q1 24
5.4%
Cash Conversion
LZ
LZ
MDGL
MDGL
Q4 25
5.63×
Q3 25
12.03×
Q2 25
Q1 25
9.89×
Q4 24
3.31×
Q3 24
2.86×
Q2 24
20.74×
Q1 24
7.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LZ
LZ

Segment breakdown not available.

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons